^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    imvotamab (IGM-2323)

    i
    Other names: IGM-2323, IGM2323, IGM 2323
    Company:
    IGM Biosciences
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    10ms
    IGM-2323-102: A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=33, Terminated, IGM Biosciences, Inc. | Trial completion date: May 2026 --> Feb 2025 | Recruiting --> Terminated; Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis demonstrated that the depth and consistency in B Cell depletion required to measure success was insufficient.
    Trial completion date • Trial termination
    |
    CRP (C-reactive protein)
    |
    imvotamab (IGM-2323)
    10ms
    IGM-2323-103: A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies (clinicaltrials.gov)
    P1, N=2, Terminated, IGM Biosciences, Inc. | N=10 --> 2 | Trial completion date: Nov 2026 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2025 --> Jan 2025; Program Discontinuation
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    imvotamab (IGM-2323)
    10ms
    IGM-2323-101: A Study of Imvotamab in Severe Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=17, Terminated, IGM Biosciences, Inc. | Trial completion date: May 2026 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Jan 2025; Company Decision.
    Trial completion date • Trial termination • Trial primary completion date
    |
    imvotamab (IGM-2323)
    1year
    IGM-2323-102: A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=40, Recruiting, IGM Biosciences, Inc. | N=24 --> 40 | Trial completion date: Jul 2025 --> May 2026 | Trial primary completion date: Feb 2025 --> May 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    imvotamab (IGM-2323)
    over1year
    A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies (clinicaltrials.gov)
    P1, N=10, Recruiting, IGM Biosciences, Inc.
    New P1 trial
    |
    imvotamab (IGM-2323)
    over1year
    IGM-2323-001: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=97, Terminated, IGM Biosciences, Inc. | Trial completion date: Oct 2024 --> Feb 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2024 --> Feb 2024; Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases prioritized.
    Trial completion date • Trial termination • Trial primary completion date
    |
    Zynlonta (loncastuximab tesirine-lpyl) • imvotamab (IGM-2323)
    over1year
    Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL (clinicaltrials.gov)
    P=N/A, N=0, No Longer Available, IGM Biosciences, Inc.
    New trial
    |
    imvotamab (IGM-2323)
    almost2years
    A Study of Imvotamab in Severe Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=18, Recruiting, IGM Biosciences, Inc. | Phase classification: P1b --> P1
    Phase classification
    |
    imvotamab (IGM-2323)
    almost2years
    A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=24, Recruiting, IGM Biosciences, Inc. | Phase classification: P1b --> P1
    Phase classification
    |
    CRP (C-reactive protein)
    |
    imvotamab (IGM-2323)
    almost2years
    A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=97, Active, not recruiting, IGM Biosciences, Inc.
    Trial completion date • Trial primary completion date
    |
    imvotamab (IGM-2323)
    2years
    A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov)
    P1b, N=24, Recruiting, IGM Biosciences, Inc.
    New P1 trial
    |
    CRP (C-reactive protein)
    |
    imvotamab (IGM-2323)
    2years
    A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=97, Active, not recruiting, IGM Biosciences, Inc. | Recruiting --> Active, not recruiting | N=260 --> 97 | Trial primary completion date: Sep 2024 --> Oct 2023
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    imvotamab (IGM-2323)